(Q36815006)

16 August 2017

1 reference

title

Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing (English)

1 reference

16 August 2017

1 reference

1

Mark Schiffman

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

16 August 2017

number of pages

9

1 reference

inferred from page(s)

published in

Cancer

1 reference

16 August 2017

volume

111

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

145-153

1 reference

Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.22751

1 reference

7 January 2021

A follow-up study of patients with cervical dysplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

Prevalence of HPV infection among females in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

Chapter 5: Updating the natural history of HPV and anogenital cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

Carcinogenicity of human papillomaviruses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

Chapter 14: Role of triage testing in cervical cancer screening.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

When to test women for human papillomavirus

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

American cancer society guideline for the early detection of cervical neoplasia and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

2001 Consensus Guidelines for the management of women with cervical cytological abnormalities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

Chapter 13: Current findings from prophylactic HPV vaccine trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

The ethics and politics of compulsory HPV vaccination

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.22751

1 reference

7 January 2021

Colposcopy at a crossroads.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

Impact of HPV testing, HPV vaccine development, and changing screening frequency on national Pap test volume: projections from the National Health Interview Survey (NHIS).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

The carcinogenicity of human papillomavirus types reflects viral evolution.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

High-risk HPV type-specific clearance rates in cervical screening

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

Adding a Test for Human Papillomavirus DNA to Cervical-Cancer Screening

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

The promise of global cervical-cancer prevention

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22751

7 January 2021

Identifiers

DOI

10.1002/CNCR.22751

1 reference

16 August 2017

1 reference